Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.30 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20600632 | 0.85 | POLB (0.41) | TGFBR1POLB | |
| SCHEMBL21722503 | 0.76 | ENPP2 (0.38) | POLBENPP2 | |
| SCHEMBL5657000 | 0.76 | CYP1A2 (0.49) | TGFBR1POLB | |
| SCHEMBL21730332 | 0.76 | TGFBR1 (0.40) | TGFBR1POLBENPP2 | |
| SCHEMBL2702226 | 0.76 | MAP3K14 (0.43) | TGFBR1POLB | |
| SCHEMBL18041473 | 0.72 | TGFBR1 (0.43) | TGFBR1 | |
| SCHEMBL30926487 | 0.72 | SCN5A (0.35) | TGFBR1 | |
| SCHEMBL22552094 | 0.72 | SCN5A (0.50) | TGFBR1 | |
| SCHEMBL21084987 | 0.71 | TGFBR1 (0.49) | TGFBR1 | |
| SCHEMBL24316477 | 0.71 | KDM4E (0.41) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122203-A1 | ADENOSINE RECEPTOR ANTAGONISTS | CROSSIGNAL THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| US-12065444-B2 | Substituted tetrazolo[1,5-a]pyrazines and tetrazolo[1,5-c]pyrimidines as adenosine receptor antagonists | CROSSIGNAL THERAPEUTICS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-20230159541-A1 | ADENOSINE RECEPTOR ANTAGONISTS | CROSSIGNAL THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122203-A1 | ADENOSINE RECEPTOR ANTAGONISTS | ADORA2A, ADORA1, ADORA3 | TGFBR1 2101/4885POLB 1466/4885GGPS1 2157/4885 |
| US-20230159541-A1 | ADENOSINE RECEPTOR ANTAGONISTS | ADORA2A, ADORA1, ADORA3 | TGFBR1 2101/4885POLB 1466/4885GGPS1 2157/4885 |
| US-12065444-B2 | Substituted tetrazolo[1,5-a]pyrazines and tetrazolo[1,5-c]pyrimidines as adenosine receptor antagonists | ADORA2A, ADORA1, P2RX5 | TGFBR1 1255/4885POLB 1968/4885GGPS1 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.